Everest Organics Board Approves Key Director Re-appointments and New Company Secretary

Everest Organics Limited , a prominent player in the pharmaceutical industry, has announced significant changes in its leadership structure. The company's Board of Directors has approved several key appointments, signaling a continuation of its current management strategy.

Leadership Continuity

The Board has given its nod for the re-appointment of Dr. Srikakarlapudi Sirisha as the Managing Director for a three-year term, commencing from August 10, 2025, to August 09, 2028. Dr. Sirisha, aged 48, holds M.B.B.S and MD degrees and has been associated with the company since 2014. She currently serves as the Chief Executive Officer and brings extensive leadership experience in various aspects of the pharmaceutical industry, including marketing, regulatory excellence, ethical governance, and Research and Development.

In a parallel move, Mr. Srikakarlapudi Harikrishna has been re-appointed as the Whole-time Director for a three-year term, from September 25, 2025, to September 24, 2028. Mr. Harikrishna, aged 46, is a mechanical engineer who joined the company in 2007. His expertise lies in new project planning and commissioning, purchase of engineering products, and regular engineering detailing of the plant.

Both these re-appointments are subject to shareholder approval at the upcoming 32nd Annual General Meeting.

New Company Secretary

The Board has also appointed Ms. Shweta Singh as the new Company Secretary and Compliance Officer, effective August 05, 2025. Ms. Singh is an associate member of the Institute of Company Secretaries of India and holds a Master's degree in Commerce. She brings over three years of experience in handling compliances under various Corporate Laws for both listed and unlisted companies.

Corporate Governance and Transparency

It's worth noting that both Dr. Sirisha and Mr. Harikrishna are promoter directors and are related to each other. This information is disclosed as part of the company's commitment to transparency and good corporate governance practices.

Financial Performance

In addition to these appointments, Everest Organics Limited has reported its unaudited financial results for the quarter ended June 30, 2025. The company has shown a significant turnaround in its performance compared to the same quarter last year.

Particulars (in ₹ Lakhs)	Q1 FY2026	Q1 FY2025	YoY Change
Revenue from Operations	5,381.32	3,244.89	65.84%
Total Income	5,436.28	3,277.12	65.89%
Profit Before Tax	216.43	(608.87)	N/A
Profit After Tax	140.52	(608.96)	N/A

The company has managed to increase its revenue from operations by 65.84% year-over-year, from ₹3,244.89 lakhs in Q1 FY2025 to ₹5,381.32 lakhs in Q1 FY2026. More importantly, Everest Organics has turned a loss of ₹608.96 lakhs in Q1 FY2025 into a profit of ₹140.52 lakhs in Q1 FY2026, showcasing a remarkable improvement in its financial performance.

These leadership re-appointments and the strong financial turnaround indicate Everest Organics' commitment to maintaining stability in its management while driving growth and profitability. The company appears to be positioning itself for continued success in the pharmaceutical sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.60%	+2.15%	+8.35%	-0.10%	+188.20%	+66.13%

Everest Organics Limited , a player in the Active Pharmaceutical Ingredients (API) sector, has reported a significant turnaround in its financial performance for the quarter ended June 30, 2025. The company's board has also approved key management reappointments and a new appointment in its recent meeting.

Financial Performance

Everest Organics posted a profit of Rs 140.52 lakhs for the quarter ended June 30, 2025, marking a substantial improvement from a loss of Rs 608.96 lakhs in the same quarter last year. The company's revenue from operations stood at Rs 5,381.32 lakhs, with domestic turnover contributing Rs 4,215.33 lakhs and export turnover accounting for Rs 1,165.99 lakhs.

Key Financial Metrics

Particulars	Q1 FY2026 (Rs in Lakhs)	Q1 FY2025 (Rs in Lakhs)
Revenue from Operations	5,381.32	3,244.89
Total Income	5,436.28	3,277.42
Profit Before Tax	216.43	(608.87)
Net Profit	140.52	(608.96)

Management Reappointments and New Appointment

The Board of Directors has approved several key management changes:

Dr. Srikakarlapudi Sirisha has been reappointed as the Managing Director for a three-year term from August 10, 2025, to August 09, 2028, subject to shareholder approval.
Mr. Srikakarlapudi Harikrishna has been reappointed as the Whole-time Director for a three-year term from September 25, 2025, to September 24, 2028, subject to shareholder approval.
Ms. Shweta Singh has been appointed as the new Company Secretary and Compliance Officer, effective August 05, 2025.

Annual General Meeting

The company has scheduled its 32nd Annual General Meeting for September 27, 2025, to be held through Video Conferencing (VC) or Other Audio Visual Means (OAVM).

Auditor's Qualification

The company's auditors, M/s. P.S.N. Ravishanker & Associates, have issued a qualified review report. The qualification highlights concerns about the company operating at enhanced production levels without necessary approvals from the Telangana State Pollution Control Board (TSPCB). This non-compliance could potentially impact the company's going concern status.

The management has stated that they are addressing this issue and have applied for Consent for Establishment for the enhancement in capacities, which is pending approval. The company has also obtained an Environmental Clearance Certificate for additional capacities.

Everest Organics Limited operates in the Active Pharmaceutical Ingredients (API) and their intermediates segment. The company's ability to navigate regulatory challenges while maintaining its growth trajectory will be crucial for its future performance.